# A Study to Evaluate the Potential Role and Clinical Application Value of Long Noncoding RNA CASC Family Members in Colorectal Cancer Based on Transcriptomic Data

**Authors:** Chao Liang, Jun Wang, Xinyu Liu

PMC · DOI: 10.1155/ijog/3881424 · International Journal of Genomics · 2025-07-24

## TL;DR

This study explores six long noncoding RNAs from the CASC family that may help predict colorectal cancer outcomes and immune responses.

## Contribution

The study identifies six CASC family lncRNAs with high diagnostic accuracy and links them to immune infiltration in colorectal cancer.

## Key findings

- Six CASC lncRNAs (CASC15, CASC16, CASC8, CASC9, CASC19, CASC18) showed high diagnostic accuracy with AUC values over 0.7.
- CASC15 expression increased with CRC progression and its knockdown reduced cancer cell metastasis in vitro.
- The six lncRNAs correlated with immune cell infiltration and interacted with proteins like LIN28B and IGF2BP2.

## Abstract

Background: Long noncoding RNA (lncRNA) CASC, crucial in colorectal cancer (CRC) progression, remains largely unexplored despite its potential.

Methods: The CRC data comes from The Cancer Genome Atlas (TCGA) database. The limma package was used to screen differentially expressed genes (DEGs), intersecting with CASC genes that yielded key hub lncRNAs. Next, the lncRNA–protein interaction network was developed applying Cytoscape software. The association between immune cell infiltration and lncRNAs was calculated using the ESTIMATE package, CIBERSORT package, and ssGSEA. Based on the survminer package to assess the correlation between hub gene expression levels and clinicopathologic features of CRC patients, cellular models were utilized to assess the mRNA expression levels and potential biological functions of the screened markers.

Results: We filtered 2326 DEGs that were notably enriched in pathways related to metastasis, cell growth, and EMT. This study found six hub lncRNAs (CASC15, CASC16, CASC8, CASC9, CASC19, and CASC18) showed a high diagnostic accuracy, with the area under the curve (AUC) values all exceeding 0.7. There were 44 proteins in the lncRNA–protein interaction network that interact with hub lncRNAs, among which both LIN28B and IGF2BP2 interact with six hub lncRNAs. Immune infiltration analysis indicated that the six hub lncRNAs were significantly correlated with the multiple types of immune cells. Pathological analysis demonstrated that the expression of CASC15 elevated with the progression of TNM staging. Cellular assays had revealed that all are significantly associated with CRC; particularly, CASC15 knockdown repressed the in vitro metastasis of CRC cells.

Conclusion: We constructed and validated a robust signature of six lncRNA CASC for predicting survival of CRC patients and characterizing the immune infiltration landscape. These results reveal that the CASC gene family could be a therapeutic target for CRC patients.

## Linked entities

- **Genes:** CASC15 (cancer susceptibility 15) [NCBI Gene 401237], CASC16 (cancer susceptibility 16) [NCBI Gene 643714], CASC8 (cancer susceptibility 8) [NCBI Gene 727677], CASC9 (cancer susceptibility 9) [NCBI Gene 101805492], CASC19 (cancer susceptibility 19) [NCBI Gene 103021165], CASC18 (cancer susceptibility 18) [NCBI Gene 101929110], LIN28B (lin-28 RNA binding posttranscriptional regulator B) [NCBI Gene 389421], IGF2BP2 (insulin like growth factor 2 mRNA binding protein 2) [NCBI Gene 10644]
- **Proteins:** LIN28B (lin-28 RNA binding posttranscriptional regulator B), IGF2BP2 (insulin like growth factor 2 mRNA binding protein 2)
- **Diseases:** colorectal cancer (MONDO:0005575), CRC (MONDO:0005575)

## Full-text entities

- **Genes:** CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, TFRC (transferrin receptor) [NCBI Gene 7037] {aka CD71, IMD46, T9, TFR, TFR1, TR}, CASC6 (cancer susceptibility 6) [NCBI Gene 101929083], CASC23 (cancer susceptibility 23) [NCBI Gene 103581031] {aka LINC01464}, CASC17 (cancer susceptibility 17) [NCBI Gene 101928165] {aka LINC00600}, CASC11 (cancer susceptibility 11) [NCBI Gene 100270680] {aka CARLO7, CARLo-7, LINC00990, MYMLR, TCONS_00014535}, IGF2 (insulin like growth factor 2) [NCBI Gene 3481] {aka C11orf43, GRDF, IGF-II, PP9974, SRS3}, CASC8 (cancer susceptibility 8) [NCBI Gene 727677] {aka CARLO1, CARLo-1, LINC00860}, CASC16 (cancer susceptibility 16) [NCBI Gene 643714] {aka LINC00918}, CLDN1 (claudin 1) [NCBI Gene 9076] {aka CLD1, ILVASC, SEMP1}, HNRNPK (heterogeneous nuclear ribonucleoprotein K) [NCBI Gene 3190] {aka AUKS, CSBP, HNRPK, TUNP}, TENM1 (teneurin transmembrane protein 1) [NCBI Gene 10178] {aka ODZ1, ODZ3, TEN-M1, TEN1, TNM, TNM1}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, CASC18 (cancer susceptibility 18) [NCBI Gene 101929110], CPSF3 (cleavage and polyadenylation specific factor 3) [NCBI Gene 51692] {aka CPSF-73, CPSF73, NEDMHS, NEDMHSN}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, LIN28B (lin-28 RNA binding posttranscriptional regulator B) [NCBI Gene 389421] {aka CSDD2}, IRS1 (insulin receptor substrate 1) [NCBI Gene 3667] {aka HIRS-1}, IGF2BP2 (insulin like growth factor 2 mRNA binding protein 2) [NCBI Gene 10644] {aka IMP-2, IMP2, VICKZ2}, MIR145 (microRNA 145) [NCBI Gene 406937] {aka MIRN145, miR-145, miRNA145}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, CASC9 (cancer susceptibility 9) [NCBI Gene 101805492] {aka ESCCAL-1, ESSCAL1, LINC00981, linc-JPH1}, CASC20 (cancer susceptibility 20) [NCBI Gene 101929244], PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, CASC19 (cancer susceptibility 19) [NCBI Gene 103021165] {aka CARLO6, CARLo-6, LINC01245}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, CEMIP (cell migration inducing hyaluronidase 1) [NCBI Gene 57214] {aka CCSP1, CEMIP1, HYBID, KIAA1199, TMEM2L}, CASC21 (cancer susceptibility 21) [NCBI Gene 103021164] {aka CARLO2, CARLo-2, LINC01244}, NOTCH3 (notch receptor 3) [NCBI Gene 4854] {aka CADASIL, CADASIL1, CARASIL1, CASIL, FPLD1, IMF2}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, LGR5 (leucine rich repeat containing G protein-coupled receptor 5) [NCBI Gene 8549] {aka FEX, GPR49, GPR67, GRP49, HG38}, AKT3 (AKT serine/threonine kinase 3) [NCBI Gene 10000] {aka MPPH, MPPH2, PKB-GAMMA, PKBG, PRKBG, RAC-PK-gamma}, CASC22 (cancer susceptibility 22) [NCBI Gene 283854] {aka LINC01373, LincRNA-ENST00000515084, TCONS_00024290}, MIR4310 (microRNA 4310) [NCBI Gene 100423013], CASC2 (cancer susceptibility 2) [NCBI Gene 255082] {aka C10orf5}, CASC15 (cancer susceptibility 15) [NCBI Gene 401237] {aka CANT, LINC00340, lnc-SOX4-1}
- **Diseases:** deaths (MESH:D003643), metastasis (MESH:D009362), lymphatic metastasis (MESH:D008207), COAD (MESH:D029424), CASC (MESH:D009369), Metastatic (MESH:D000092182), carcinogenesis (MESH:D063646), CRC (MESH:D015179)
- **Chemicals:** paraformaldehyde (MESH:C003043), PBS (MESH:D007854), streptomycin (MESH:D013307), CO2 (MESH:D002245), Lipofectamine (MESH:C086724), berberine (MESH:D001599), TRIzol (MESH:C411644), iron (MESH:D007501), penicillin (MESH:D010406), crystal violet (MESH:D005840), Leibovitz's L15 (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** rs6983267
- **Cell lines:** SW1116 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0544), SNL-448 — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_JR66), NCM460 — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0460), SNL-519 — Homo sapiens (Human), Maroteaux-Lamy syndrome, Finite cell line (CVCL_V775), SNM-001A — Homo sapiens (Human), Melanoma, Cancer cell line (CVCL_B4K8), HCT116 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_0291), HT29 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0320), SNM-007A — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_A4DH)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12313387/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12313387/full.md

## References

65 references — full list in the complete paper: https://tomesphere.com/paper/PMC12313387/full.md

---
Source: https://tomesphere.com/paper/PMC12313387